Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.

The study, published July 8 in JAMA Internal Medicine, is thought to be the first head-to-head comparison of the two blockbuster weight loss drugs.

Since Zepbound was approved for weight loss in late 2023, it appeared to have an advantage over Wegovy. Patients taking the highest dose of Zepbound lost around 21% of their body weight over 72 weeks, compared to around 15% for patients on Wegovy after 68 weeks.

But it was difficult to make a direct comparison without a study that looked at both drugs, which are part of a new class of medications called GLP-1s.

Read more at NBC News >>